Assessing immune response to improve immunosuppression after liver transplantation
Using Transcriptional Assessment of Immune Response to Assess Immunosuppression After Liver Transplantation
This study is testing a new way to personalize medication for people who have had a liver transplant to see if it can improve their health and the health of their new liver.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | University of Florida Academic / other |
| Locations | 1 site (Gainesville, Florida) |
| Trial ID | NCT06063213 on ClinicalTrials.gov |
What this trial studies
This study aims to develop a quantitative monitoring protocol for liver allografts and validate a personalized medicine approach for immunosuppression dosing in liver transplant recipients. The investigators will utilize a computational method called Phenotypic Personalized Medicine (PPM) to create patient-specific visual maps that guide drug dosing based on individual responses. By employing clinically validated markers of immune state and allograft injury, the study seeks to optimize immunosuppression and improve patient and graft outcomes. The approach builds on previous pilot studies that demonstrated better drug management with PPM compared to standard care.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older who are at least one month post-liver transplantation.
Not a fit: Patients who are unwilling to provide informed consent or have received previous bone marrow or stem cell transplants may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved outcomes for liver transplant patients by personalizing immunosuppression therapy.
How similar studies have performed: Previous studies using similar personalized medicine approaches have shown success in improving drug management in transplant patients.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * At least 18 years of age * At least one-month post-transplant * Recipient of a liver transplant alone or a simultaneous liver-kidney transplant Exclusion Criteria: * Unwilling to provide informed consent * Recipient of a previous bone marrow or stem cell transplant * Pregnant * Unlikely to be able to comply with the study requirements, as determined by the PI
Where this trial is running
Gainesville, Florida
- University of Florida — Gainesville, Florida, United States (Recruiting)
Study contacts
- Study coordinator: Ali Zarrinpar, MD, PhD
- Email: azarrinpar@ufl.edu
- Phone: (352) 265-0606
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.